WO2022171203A1 - 一种乳双歧杆菌及其应用 - Google Patents
一种乳双歧杆菌及其应用 Download PDFInfo
- Publication number
- WO2022171203A1 WO2022171203A1 PCT/CN2022/085752 CN2022085752W WO2022171203A1 WO 2022171203 A1 WO2022171203 A1 WO 2022171203A1 CN 2022085752 W CN2022085752 W CN 2022085752W WO 2022171203 A1 WO2022171203 A1 WO 2022171203A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bifidobacterium lactis
- cfu
- pharmaceutical composition
- food composition
- bifidobacterium
- Prior art date
Links
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 title claims abstract description 136
- 229940009289 bifidobacterium lactis Drugs 0.000 title claims abstract description 136
- LZRYNUIYHHQTRL-NBZVOYHKSA-N (2s)-1-[(2s)-6-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]-2-[(1-carboxy-3-phenylpropyl)amino]hexanoyl]pyrrolidine-2-carboxylic acid Chemical compound N([C@@H](CCCCNC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1)C(=O)N1[C@@H](CCC1)C(O)=O)C(C(=O)O)CCC1=CC=CC=C1 LZRYNUIYHHQTRL-NBZVOYHKSA-N 0.000 claims abstract description 109
- 239000000203 mixture Substances 0.000 claims abstract description 80
- 244000005700 microbiome Species 0.000 claims abstract description 20
- 238000011161 development Methods 0.000 claims abstract description 19
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 14
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 13
- 206010003805 Autism Diseases 0.000 claims abstract description 13
- 208000020706 Autistic disease Diseases 0.000 claims abstract description 13
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims abstract description 13
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 12
- 230000036506 anxiety Effects 0.000 claims abstract description 12
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 8
- 208000036640 Asperger disease Diseases 0.000 claims abstract description 6
- 201000006062 Asperger syndrome Diseases 0.000 claims abstract description 6
- 208000007386 hepatic encephalopathy Diseases 0.000 claims abstract description 6
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 5
- 208000016620 Tourette disease Diseases 0.000 claims abstract description 5
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims abstract 2
- 239000006041 probiotic Substances 0.000 claims description 80
- 235000018291 probiotics Nutrition 0.000 claims description 80
- 235000013305 food Nutrition 0.000 claims description 62
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 241000894006 Bacteria Species 0.000 claims description 37
- 230000001580 bacterial effect Effects 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 29
- 230000000968 intestinal effect Effects 0.000 claims description 26
- 230000012010 growth Effects 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 235000013336 milk Nutrition 0.000 claims description 16
- 239000008267 milk Substances 0.000 claims description 16
- 210000004080 milk Anatomy 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 15
- 230000001737 promoting effect Effects 0.000 claims description 15
- 235000013361 beverage Nutrition 0.000 claims description 14
- 229920001542 oligosaccharide Polymers 0.000 claims description 13
- 230000037396 body weight Effects 0.000 claims description 12
- 235000013406 prebiotics Nutrition 0.000 claims description 11
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 241000186000 Bifidobacterium Species 0.000 claims description 9
- 235000013351 cheese Nutrition 0.000 claims description 9
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 8
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 8
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 8
- 235000015140 cultured milk Nutrition 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- -1 isomalt oligosaccharides Chemical class 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 241000605059 Bacteroidetes Species 0.000 claims description 5
- 241000192125 Firmicutes Species 0.000 claims description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 5
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 5
- 229930003779 Vitamin B12 Natural products 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 5
- 235000012661 lycopene Nutrition 0.000 claims description 5
- 229960004999 lycopene Drugs 0.000 claims description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 5
- 239000001751 lycopene Substances 0.000 claims description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 5
- 235000019163 vitamin B12 Nutrition 0.000 claims description 5
- 239000011715 vitamin B12 Substances 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- 241001608234 Faecalibacterium Species 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 241000605861 Prevotella Species 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 230000035622 drinking Effects 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 4
- 229940029339 inulin Drugs 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 235000020183 skimmed milk Nutrition 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 3
- 241001202853 Blautia Species 0.000 claims description 3
- 244000019459 Cynara cardunculus Species 0.000 claims description 3
- 235000019106 Cynara scolymus Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 240000008892 Helianthus tuberosus Species 0.000 claims description 3
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000294 Resistant starch Polymers 0.000 claims description 3
- 241001409321 Siraitia grosvenorii Species 0.000 claims description 3
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 3
- 244000228451 Stevia rebaudiana Species 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 230000003579 anti-obesity Effects 0.000 claims description 3
- 235000016520 artichoke thistle Nutrition 0.000 claims description 3
- 239000007961 artificial flavoring substance Substances 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 235000019219 chocolate Nutrition 0.000 claims description 3
- 239000001905 cichorium intybus l. root extract Substances 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 239000008369 fruit flavor Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000905 isomalt Substances 0.000 claims description 3
- 235000010439 isomalt Nutrition 0.000 claims description 3
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 3
- 229940116298 l- malic acid Drugs 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 239000000845 maltitol Substances 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 235000020786 mineral supplement Nutrition 0.000 claims description 3
- 238000010606 normalization Methods 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 3
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021254 resistant starch Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 229940035936 ubiquinone Drugs 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000019195 vitamin supplement Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims 1
- 244000263375 Vanilla tahitensis Species 0.000 claims 1
- 229960003500 triclosan Drugs 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 210000000936 intestine Anatomy 0.000 abstract 2
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000036630 mental development Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 47
- 230000000529 probiotic effect Effects 0.000 description 41
- 239000000902 placebo Substances 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 27
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 27
- 239000002158 endotoxin Substances 0.000 description 23
- 244000005709 gut microbiome Species 0.000 description 22
- 229920006008 lipopolysaccharide Polymers 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 12
- 229930182843 D-Lactic acid Natural products 0.000 description 11
- 230000006399 behavior Effects 0.000 description 11
- 229940022769 d- lactic acid Drugs 0.000 description 11
- 230000033001 locomotion Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000003870 intestinal permeability Effects 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 230000008468 bone growth Effects 0.000 description 7
- 150000004666 short chain fatty acids Chemical class 0.000 description 7
- 235000021391 short chain fatty acids Nutrition 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 239000005913 Maltodextrin Substances 0.000 description 5
- 241000736262 Microbiota Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 230000007149 gut brain axis pathway Effects 0.000 description 5
- 208000013403 hyperactivity Diseases 0.000 description 5
- 230000009191 jumping Effects 0.000 description 5
- 229940035034 maltodextrin Drugs 0.000 description 5
- 230000006386 memory function Effects 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 235000013618 yogurt Nutrition 0.000 description 5
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000001930 leg bone Anatomy 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 230000003938 response to stress Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 208000037487 Endotoxemia Diseases 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000008450 motivation Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000011273 social behavior Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000008718 systemic inflammatory response Effects 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 230000002747 voluntary effect Effects 0.000 description 3
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000007415 Anhedonia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101800001586 Ghrelin Proteins 0.000 description 2
- 102400000442 Ghrelin-28 Human genes 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241001453443 Rothia <bacteria> Species 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 244000290333 Vanilla fragrans Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 235000013611 frozen food Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003370 grooming effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000007150 microbiota gut brain axis Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- BIWLELKAFXRPDE-UHFFFAOYSA-N zeta-Carotene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)CCC=C(C)CCC=C(C)C BIWLELKAFXRPDE-UHFFFAOYSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 241000701474 Alistipes Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101100151946 Caenorhabditis elegans sars-1 gene Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241001600130 Comamonadaceae Species 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 241001443882 Coprobacillus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000036115 Faecal volume increased Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 1
- 101000875780 Homo sapiens Ubiquinone biosynthesis protein COQ4 homolog, mitochondrial Proteins 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 101150034559 IGF1R gene Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 241001134638 Lachnospira Species 0.000 description 1
- 241001112693 Lachnospiraceae Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 101710129981 Pituitary-specific positive transcription factor 1 Proteins 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 241000095588 Ruminococcaceae Species 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000123710 Sutterella Species 0.000 description 1
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102100035953 Ubiquinone biosynthesis protein COQ4 homolog, mitochondrial Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010888 cage effect Methods 0.000 description 1
- 230000003047 cage effect Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 230000008546 entero-endocrine signaling Effects 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000021105 fermented cheese Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 101150102318 fre gene Proteins 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000009263 intestinal permeability test Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 101150062288 ubiB gene Proteins 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 208000010603 vasculitis due to ADA2 deficiency Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present disclosure relates to the technical field of microorganisms, and in particular, to a Bifidobacterium lactis and its application.
- gut bacteria can affect the growth and development of the host, and some flora can mediate the growth and development of the host by affecting growth hormone (GH)/insulin-like growth factor-1 (IGF-1). Both germ-free and antibiotic-treated mice exhibited reduced growth and were associated with reduced levels of ghrelin, growth hormone and IGF-1. In addition, in mice and humans, lack of microbes can lead to maturation and growth restriction, such as chronic malnutrition, anorexia nervosa, growth retardation, short stature, and even neurological and immune system abnormalities. Insulin-like growth factor 1 (IGF-1), a hormone with a known effect on bone growth, was significantly increased in serum and liver and adipose tissue with increased gut microbial colonization.
- IGF-1 Insulin-like growth factor 1
- IGF-1 Insulin-like growth factor 1
- Exogenous IGF-1 can promote longitudinal growth of the femur, and after cartilage-specific insulin-like growth factor I receptor (Igf1r) deletion, IGF-1 was observed to affect growth plate maturation and secondary ossification center formation.
- IGF-1 can promote osteoblasts (including affecting bone formation and bone resorption, respectively). Therefore, alterations in the gut microbiota can promote bone formation and resorption, resulting in net bone growth, and the microbiota can promote bone growth and remodeling by inducing IGF-1.
- Direct supplementation with probiotics, prebiotics, or short-chain fatty acids (SCFAs) produced after microbial fermentation of cellulose has the potential to induce an increase in IGF-1, which in turn affects bone growth and health.
- SCFAs short-chain fatty acids
- gut microbes can regulate brain function and behavior through the gut-brain axis.
- gut microbiota and brain via autonomic, enteric, immune system, olfactory system, enteroendocrine signaling, neurotransmitters, branched-chain amino acids, bile acids, short-chain fatty acids, spinal cord, hypothalamic-pituitary-adrenal axis, peptides Glycans and other pathways and mediators communicate bidirectionally.
- Two-way communication between the gut microbiota and the central nervous system, the microbiota-gut-brain axis can affect neurodevelopment and function in animals, thereby affecting social behavior.
- This bidirectional influence of the microbiota-gut-brain axis is influenced by internal factors such as gender and genetics, as well as external factors such as environment, diet, genetics, and stress. Therefore, the gut microbiota is involved in the pathogenesis of a variety of neurological-related diseases, and at the same time, psychological and behavioral responses will in turn affect the composition or function of the gut microbiota.
- microbiota-targeted interventions hold promise for gut microbiota-related disorders such as anxiety, depression, schizophrenia, ADHD, tics, Parkinson’s, Alzheimer’s, and autism and other social barriers. Take, for example, attention-deficit/hyperactivity disorder (ADHD), the most common neurobehavioral developmental disorder in childhood.
- ADHD attention-deficit/hyperactivity disorder
- the main manifestations are easily distracted attention disproportionate to the age of the children, narrowed attention span, excessive activity regardless of the occasion, emotional impulsiveness and often accompanied by cognitive impairment, conduct disorder and learning difficulties.
- the incidence of ADHD is high, and it has obvious adverse effects on patients' academic, family and social life. However, treatments for ADHD are still lacking.
- the present disclosure provides a Bifidobacterium lactis and an application thereof.
- the Bifidobacterium lactis can improve intestinal metabolic disorders and normalize the composition of the intestinal microbiome, thereby effectively resisting obesity, promoting the growth and development of children and adolescents, and promoting their intellectual development;
- the Bifidobacterium lactis can also effectively improve intestinal permeability and reduce the levels of LPS and D-lactic acid in the blood, thereby preventing and treating mental disorders, including anxiety, depression, and attention deficit hyperactivity disorder. , autism, autism, schizophrenia, hepatic encephalopathy, anorexia nervosa, Tourette's syndrome, Asperger's syndrome.
- a first aspect of the present disclosure provides a Bifidobacterium lactis, the Bifidobacterium lactis is Bifidobacterium lactis BL-11, and the preservation number of the Bifidobacterium lactis BL-11 is CGMCC No.20847 .
- the second aspect of the present disclosure also provides a Bifidobacterium lactis preparation, wherein the preparation is solid bacteria powder or liquid drinking liquid; the Bifidobacterium lactis is the Bifidobacterium lactis described in the first aspect of the disclosure.
- the third aspect of the present disclosure also provides the use of the above-mentioned Bifidobacterium lactis in preparing a food composition or a pharmaceutical composition for improving intestinal metabolic disorder and promoting the normalization of intestinal microbiome composition.
- the fourth aspect of the present disclosure also provides the application of the above-mentioned Bifidobacterium lactis in the preparation of an anti-obesity food composition or a pharmaceutical composition for children and adolescents.
- the fifth aspect of the present disclosure also provides the application of the above-mentioned Bifidobacterium lactis in preparing a food composition or a pharmaceutical composition for promoting the growth and development of children and adolescents.
- the sixth aspect of the present disclosure also provides the use of the above-mentioned Bifidobacterium lactis in preparing a food composition or a pharmaceutical composition for promoting height increase in children and adolescents.
- the seventh aspect of the present disclosure also provides the application of the above-mentioned Bifidobacterium lactis in preparing a food composition or a pharmaceutical composition for promoting the intellectual development of children and adolescents.
- the content of Bifidobacterium lactis BL-11 is 1-25 parts by weight, preferably 1-15 parts by weight;
- Bifidobacterium lactis BL-11 is used in the form of a living cell of the Bifidobacterium lactis BL-11, an inactivated cell of the Bifidobacterium lactis BL-11, or an extract of the Bifidobacterium lactis BL-11 .
- the viable count of the Bifidobacterium lactis BL-11 is 1.0 ⁇ 10 6 to 1.5 ⁇ 10 12 CFU/g, preferably 3.0 ⁇ 10 10 to 5.0 ⁇ 10 11 CFU/g.
- the food composition is one or more of fermented milk, cheese, beverages containing milk, solid beverages, and milk powder.
- the dosage of Bifidobacterium lactis BL-11 is 2.0 ⁇ 10 6 CFU ⁇ 1.5 ⁇ 10 11 CFU/kg/day, preferably 3.0 ⁇ 10 4 CFU ⁇ 8.0 ⁇ 10 10 CFU/kg/day.
- the eighth aspect of the present disclosure provides the use of the above-mentioned Bifidobacterium lactis in preparing a food composition or a pharmaceutical composition for preventing and treating mental disorders.
- the mental disorder includes anxiety, depression, attention deficit hyperactivity disorder, autism, autism, schizophrenia, hepatic encephalopathy, anorexia nervosa, Tourette's syndrome, Asperger's syndrome.
- the food composition or pharmaceutical composition also contains one or more of skim milk powder, trehalose, fructooligosaccharide, lactose, glucose, sucrose, L-sodium ascorbate, L-malic acid, L-lactic acid, etc. kind of combination.
- the food composition or pharmaceutical composition further contains flavoring agents, sweeteners, thickening agents, stabilizers, surfactants, lubricants, acid neutralizers, dispersing agents, buffers or buffers, Debitterizers, pH stabilizers, preservatives, sugar removers and/or colorants such as lactitol, sorbitol, maltitol, aspartame, stevia, monk fruit, sucralose, xylitol, vanilla , chocolate, fruit flavors, artificial flavors, or mixtures or combinations thereof.
- flavoring agents such as lactitol, sorbitol, maltitol, aspartame, stevia, monk fruit, sucralose, xylitol, vanilla , chocolate, fruit flavors, artificial flavors, or mixtures or combinations thereof.
- the food composition or pharmaceutical composition further contains vitamins, minerals and/or dietary supplements or prebiotic nutrients, at least one prebiotic, wherein optionally, the prebiotic comprises inulin, Artichoke extract, chicory root extract, Jerusalem artichoke root extract, fructooligosaccharides, galactooligosaccharides, isomalt oligosaccharides, xylo-oligosaccharides, stachyose, mannose oligosaccharides, arabino-oligosaccharides, resistance Dextrin, resistant starch, or mixtures or combinations thereof.
- the prebiotic comprises inulin, Artichoke extract, chicory root extract, Jerusalem artichoke root extract, fructooligosaccharides, galactooligosaccharides, isomalt oligosaccharides, xylo-oligosaccharides, stachyose, mannose oligosaccharides, arabino-oligosaccharides, resistance Dextri
- the food composition or pharmaceutical composition further contains ubiquinone (CoQ10), lycopene, beta-carotene, tryptophan, vitamin B6, vitamin B12, or a mixture or combination thereof.
- ubiquinone CoQ10
- lycopene beta-carotene
- tryptophan vitamin B6, vitamin B12, or a mixture or combination thereof.
- the food composition or pharmaceutical composition further contains probiotics, wherein optionally, the probiotics comprise cultured or fecal-extracted microorganisms or bacteria or bacterial components, and optionally, the Bacteria or bacterial components including or derived from Lactobacillus, Bifidobacterium, E coli, Prevotella, Faecalibacterium, Brautia (Blautia), Bacteroidetes (Bacteroidetes), Firmicutes (Firmicutes) and equivalents, or mixtures or combinations thereof.
- the probiotics comprise cultured or fecal-extracted microorganisms or bacteria or bacterial components
- Bacteria or bacterial components including or derived from Lactobacillus, Bifidobacterium, E coli, Prevotella, Faecalibacterium, Brautia (Blautia), Bacteroidetes (Bacteroidetes), Firmicutes (Firmicutes) and equivalents, or mixtures or combinations thereof.
- the content of the Bifidobacterium lactis BL-11 is 0.5-20 parts by weight, preferably 1-15 parts by weight; the Bifidobacterium lactis BL-11 BL-11 is used in the form of the living cell of the Bifidobacterium lactis BL-11, the inactivated cell of the Bifidobacterium lactis BL-11 or the extract of the Bifidobacterium lactis BL-11;
- the viable count of Bifidobacterium lactis BL-11 is 1.0 ⁇ 10 6 to 1.5 ⁇ 10 12 CFU/g, preferably 3.0 ⁇ 10 10 to 5.0 ⁇ 10 11 CFU/g.
- the food composition is one or more of fermented milk, cheese, beverages containing milk, solid beverages, and milk powder.
- the dosage of Bifidobacterium lactis BL-11 is 2.0 ⁇ 10 9 CFU ⁇ 1.5 ⁇ 10 11 CFU/kg/day, preferably 3.0 ⁇ 10 4 CFU ⁇ 8.0 ⁇ 10 10 CFU/kg/day.
- the food composition or pharmaceutical composition can be in the form of powders, lozenges, liquids, chewing gums, gummies, tableted candies, yogurt, milk, cheese, ice cream, frozen foods, Health food, medicine or feed.
- the Bifidobacterium lactis BL-11 of the present disclosure can improve intestinal permeability and reduce LPS and D-lactic acid levels in blood.
- the Bifidobacterium lactis BL-11 of the present disclosure can be used to promote voluntary active activities, improve the memory function of one-time avoidance response, and improve anhedonia caused by stressful stimuli.
- the probiotics provided by the present disclosure can effectively improve metabolic disorders and normalize the composition of intestinal microbiome, promote the growth and development of children and adolescents, improve intestinal permeability, reduce LPS in blood, D- lactate levels, thereby acting to prevent and treat mental disorders including anxiety, depression, attention deficit hyperactivity disorder, autism, autism, schizophrenia, hepatic encephalopathy, anorexia nervosa, Tourette's , Asperger's syndrome.
- Bifidobacterium lactis BL-11 classified as Bifidobacterium lactis (Bifidobacterium lactis)
- Bifidobacterium lactis Bifidobacterium lactis
- Fig. 1 is a microscopic view of Bifidobacterium lactis BL-11.
- Figures 3 and 4 are the lengths of the femurs of mice treated with antibiotics and probiotics.
- Figure 5 is the length of mouse leg bones after antibiotic and probiotic treatment.
- Figure 6 shows the changes in the diversity of intestinal flora in mice treated with two probiotics.
- Figure 7 is the ratio of bifidobacteria and lactobacilli in the intestinal tract of mice treated with two probiotics.
- Figure 8 is a heat map analysis of the gut microbiota composition of mice treated with two probiotics.
- Figure 9 is the change in human height from 0 to 12 weeks before and after taking probiotics or placebo.
- Figure 10 is the change in body weight from 0 to 12 weeks before and after taking probiotics or placebo.
- Figure 11 shows symptom improvement before and after taking probiotics or placebo.
- Figure 12 shows the composition of gut microbiota at the genus level before and after taking probiotics or placebo.
- Figure 13 is a comparison of the metabolic pathway levels of gut microbiota before and after taking probiotics or placebo.
- Figure 14 shows the composition of gut microbiota at the phylum level before and after taking probiotics or placebo.
- Figure 15 is a comparison of the composition of representative bacterial species in the intestinal flora before and after taking probiotics or placebo.
- Figure 16 is a comparison of the gut microbiota at the functional gene level before and after taking probiotics or placebo.
- Figure 17 is a comparison of gut microbiota levels in KO before and after taking probiotics or placebo.
- Figure 18 is a comparison of the metabolic pathway levels of gut microbiota before and after taking probiotics or placebo.
- Figure 19 is a graph of the results of the intestinal permeability assay.
- Fig. 20 is a diagram showing the composition of the intestinal flora of each group at the genus level.
- Figure 21 is the difference of Bifidobacterium between the two groups.
- Figure 22 is the alpha diversity index results.
- Figure 23 is the PCoA analysis result of the beta diversity index analysis.
- a first aspect of the present disclosure provides a Bifidobacterium lactis, the Bifidobacterium lactis is Bifidobacterium lactis BL-11, the preservation number of the Bifidobacterium lactis BL-11 is CGMCC No.20847.
- the second aspect of the present disclosure also provides a Bifidobacterium lactis preparation, wherein the preparation is solid bacteria powder or liquid drinking liquid; the Bifidobacterium lactis is the Bifidobacterium lactis described in the first aspect of the disclosure.
- the third aspect of the present disclosure also provides the use of the above-mentioned Bifidobacterium lactis in preparing a food composition or a pharmaceutical composition for improving intestinal metabolic disorder and promoting the normalization of intestinal microbiome composition.
- the fourth aspect of the present disclosure also provides the use of the above-mentioned Bifidobacterium lactis in preparing an anti-obesity food composition or a pharmaceutical composition for children and adolescents.
- the fifth aspect of the present disclosure also provides the application of the above-mentioned Bifidobacterium lactis in preparing a food composition or a pharmaceutical composition for promoting the growth and development of children and adolescents.
- the sixth aspect of the present disclosure also provides the use of the above-mentioned Bifidobacterium lactis in preparing a food composition or a pharmaceutical composition for promoting height increase in children and adolescents.
- the seventh aspect of the present disclosure also provides the application of the above-mentioned Bifidobacterium lactis in preparing a food composition or a pharmaceutical composition for promoting the intellectual development of children and adolescents.
- the content of Bifidobacterium lactis BL-11 is 1-25 parts by weight, preferably 1-15 parts by weight;
- Bifidobacterium lactis BL-11 is used in the form of a living cell of the Bifidobacterium lactis BL-11, an inactivated cell of the Bifidobacterium lactis BL-11, or an extract of the Bifidobacterium lactis BL-11 .
- the viable count of the Bifidobacterium lactis BL-11 is 1.0 ⁇ 10 6 to 1.5 ⁇ 10 12 CFU/g, preferably 3.0 ⁇ 10 10 to 5.0 ⁇ 10 11 CFU/g.
- the food composition is one or more of fermented milk, cheese, beverages containing milk, solid beverages, and milk powder.
- the dosage of Bifidobacterium lactis BL-11 is 2.0 ⁇ 10 6 CFU ⁇ 1.5 ⁇ 10 11 CFU/kg/day, preferably 3.0 ⁇ 10 4 CFU ⁇ 8.0 ⁇ 10 10 CFU/kg/day.
- the eighth aspect of the present disclosure provides the use of the above-mentioned Bifidobacterium lactis in preparing a food composition or a pharmaceutical composition for preventing and treating mental disorders.
- the mental disorder includes anxiety, depression, attention deficit hyperactivity disorder, autism, autism, schizophrenia, hepatic encephalopathy, anorexia nervosa, Tourette's syndrome, Asperger's syndrome.
- the food composition or pharmaceutical composition also contains one or more of skim milk powder, trehalose, fructooligosaccharide, lactose, glucose, sucrose, L-sodium ascorbate, L-malic acid, L-lactic acid, etc. kind of combination.
- the food composition or pharmaceutical composition further contains flavoring agents, sweeteners, thickening agents, stabilizers, surfactants, lubricants, acid neutralizers, dispersing agents, buffers or buffers, Debitterizers, pH stabilizers, preservatives, sugar removers and/or colorants such as lactitol, sorbitol, maltitol, aspartame, stevia, monk fruit, sucralose, xylitol, vanilla , chocolate, fruit flavors, artificial flavors, or mixtures or combinations thereof.
- flavoring agents such as lactitol, sorbitol, maltitol, aspartame, stevia, monk fruit, sucralose, xylitol, vanilla , chocolate, fruit flavors, artificial flavors, or mixtures or combinations thereof.
- the food composition or pharmaceutical composition further contains vitamins, minerals and/or dietary supplements or prebiotic nutrients, at least one prebiotic, wherein optionally, the prebiotic comprises inulin, Artichoke extract, chicory root extract, Jerusalem artichoke root extract, fructooligosaccharides, galactooligosaccharides, isomalt oligosaccharides, xylo-oligosaccharides, stachyose, mannose oligosaccharides, arabino-oligosaccharides, resistance Dextrin, resistant starch, or mixtures or combinations thereof.
- the prebiotic comprises inulin, Artichoke extract, chicory root extract, Jerusalem artichoke root extract, fructooligosaccharides, galactooligosaccharides, isomalt oligosaccharides, xylo-oligosaccharides, stachyose, mannose oligosaccharides, arabino-oligosaccharides, resistance Dextri
- the food composition or pharmaceutical composition further contains ubiquinone (CoQ10), lycopene, beta-carotene, tryptophan, vitamin B6, vitamin B12, or a mixture or combination thereof.
- ubiquinone CoQ10
- lycopene beta-carotene
- tryptophan vitamin B6, vitamin B12, or a mixture or combination thereof.
- the food composition or pharmaceutical composition further contains probiotics, wherein optionally, the probiotics comprise cultured or fecal-extracted microorganisms or bacteria or bacterial components, and optionally, the Bacteria or bacterial components including or derived from Lactobacillus, Bifidobacterium, E coli, Prevotella, Faecalibacterium, Brautia (Blautia), Bacteroidetes (Bacteroidetes), Firmicutes (Firmicutes) and equivalents, or mixtures or combinations thereof.
- the probiotics comprise cultured or fecal-extracted microorganisms or bacteria or bacterial components
- Bacteria or bacterial components including or derived from Lactobacillus, Bifidobacterium, E coli, Prevotella, Faecalibacterium, Brautia (Blautia), Bacteroidetes (Bacteroidetes), Firmicutes (Firmicutes) and equivalents, or mixtures or combinations thereof.
- the content of the Bifidobacterium lactis BL-11 is 0.5-20 parts by weight, preferably 1-15 parts by weight; the Bifidobacterium lactis BL-11 BL-11 is used in the form of the living cell of the Bifidobacterium lactis BL-11, the inactivated cell of the Bifidobacterium lactis BL-11 or the extract of the Bifidobacterium lactis BL-11;
- the viable count of Bifidobacterium lactis BL-11 is 1.0 ⁇ 10 6 to 1.5 ⁇ 10 12 CFU/g, preferably 3.0 ⁇ 10 10 to 5.0 ⁇ 10 11 CFU/g.
- the food composition is one or more of fermented milk, cheese, beverages containing milk, solid beverages, and milk powder.
- the dosage of Bifidobacterium lactis BL-11 is 2.0 ⁇ 10 9 CFU ⁇ 1.5 ⁇ 10 11 CFU/kg/day, preferably 3.0 ⁇ 10 4 CFU ⁇ 8.0 ⁇ 10 10 CFU/kg/day.
- the food composition or pharmaceutical composition can be in the form of powders, lozenges, liquids, chewing gums, gummies, tableted candies, yogurt, milk, cheese, ice cream, frozen foods, Health food, medicine or feed.
- the Bifidobacterium lactis BL-11 of the present disclosure can improve intestinal permeability and reduce LPS and D-lactic acid levels in blood.
- the Bifidobacterium lactis BL-11 of the present disclosure can be used to promote voluntary active activities, improve the memory function of one-time avoidance response, and improve anhedonia caused by stressful stimuli.
- This example is used to illustrate Bifidobacterium lactis BL-11 and its performance characteristics.
- Bifidobacterium lactis BL-11 was observed under a microscope, and the results are shown in Figure 1. The physical and chemical test results are shown in Tables 1 and 2.
- + means able to metabolize; - means unable to metabolize.
- Bifidobacterium is a genus of bacteria that are generally not acid-fast.
- the artificial gastric juice and intestinal juice tolerance of Bifidobacterium lactis BL-11 of the present invention were tested, and at the same time, Bifidobacterium lactis Bb, which has excellent acid resistance and can survive through the gastrointestinal tract, is used in the laboratory. -XX for comparison.
- the test results of the survival rate of the BL-11 strain in artificial gastric acid are shown in Table 3.
- the survival rate of viable bacteria of Bb-XX was 44.7% when Bb-XX was treated in artificial gastric juice for 1h, and the survival rate of viable bacteria was 29.5% after treatment for 3h;
- the survival rate of Bifidobacterium lactis BL-11 of the present invention was 86.2% when treated for 1 hour, and the survival rate of viable bacteria was 39.5% when treated for 3 hours. It is shown that the Bifidobacterium lactis BL-11 of the present invention has relatively good gastric acid resistance, and most of it can smoothly pass through the stomach and reach the intestinal tract to exert a probiotic effect.
- the Bifidobacterium lactis BL-11 of the present invention is inoculated into the MRS liquid medium, anaerobic culture is carried out at 37° C. for 48 hours, and the number of viable bacteria of Bifidobacterium lactis BL-11 in the culture solution is counted to be 3.7 ⁇ 10 9 CFU/mL,
- the culture stock solution was orally administered to the mice at a ratio of 20.0 mL/kg body weight for 3 consecutive days, and then observed for 7 days. Healthy male BALB/C mice, 6-8 weeks old, 16-18g, maintained at room temperature (25 ⁇ 2°C), relative humidity (55 ⁇ 2)%, 12h/12h light, free food and water. The results showed that compared with the control group, no toxic reaction or death was observed in the culture stock of Bifidobacterium lactis BL-11, and there was no statistical difference in the weight gain of the mice (p>0.05).
- Bifidobacterium lactis BL-11 The antibiotic susceptibility of Bifidobacterium lactis BL-11 was evaluated by the method of SN/T 1944-2007 "Determination of Bacterial Resistance in Animals and Their Products". The evaluation results showed that Bifidobacterium lactis BL-11 was sensitive to Ampicillin, Penicillin G, Erythromycin, Chloramphenicol, Clindamycin, Vancomycin and Tetracycline. It meets the requirements of the European Food Safety Authority (European Food Safety Authority) for the evaluation of drug resistance of edible bacteria. Bifidobacterium lactis BL-11 does not contain exogenous antibiotic resistance genes and is safe to eat.
- This example is used to illustrate the functional characteristics of Bifidobacterium lactis BL-11 in promoting growth and development.
- Microbiota which promotes bone formation and resorption, resulting in net bone growth.
- the microbiota induces the hormone-like insulin growth factor 1 (IGF-1), which promotes bone growth and remodeling.
- IGF-1 hormone-like insulin growth factor 1
- SCFAs Short-chain fatty acids
- mice 2-month-old female BALB/c mice were treated with antibiotics and probiotics and housed under SPF conditions. Thirty mice were pooled and randomly assigned to treatment groups to minimize cage effects. Antibiotics were a mixture of 0.2 mg/mL gentamicin, 0.15 mg/mL ciprofloxacin, 2 mg/mL streptomycin, and 1 mg/mL bacitracin.
- mice were treated with an antibiotic mixture added to their drinking water for 2 weeks to deplete the microorganisms, and then the mice were divided into three groups of 10 mice, one group served as a control group, fed normally, and the other two groups were given probiotics
- Bacteria group: BL-11 or Bb-XX were added to the water, respectively, and fed continuously for 4 weeks.
- 3% (g/100 mL) sucrose was added to all water to ensure palatability as specified by the animal facility.
- the aqueous solution was freshly prepared and changed twice a week.
- serum was prepared from blood samples collected by cardiac puncture using serum separator tubes after mice were sacrificed and using the murine IGF-1 standard ABTS ELISA development kit (PeproTech).
- the lengths of the femurs of mice fed with normal feeding (CK), BL-11 and Bb-XX are shown in Figure 4, and the lengths of leg bones are shown in Figure 3.
- the length of leg bones of mice fed BL-11 was significantly different from that of the control group (P ⁇ 0.05), while the length of leg bones of mice fed Bb-XX was not significantly different from that of the control group (P ⁇ 0.05).
- Data are shown as mean ⁇ SD, and t-test was used to test whether the difference was significant. *P ⁇ 0.05; **P ⁇ 0.01; ***P ⁇ 0.001.
- mice Both germ-free and antibiotic-treated mice exhibited reduced growth, reduced levels of ghrelin, growth hormone, and IGF, and gut microbiome disturbances, leading to growth restriction in mice. After the mice were treated with antibiotics, they were given probiotics to detect the serum IGF-1 level of the mice. The results are shown in Figure 5. After the antibiotic treatment, the mice that took probiotics increased the level of IGF-1 in the serum. , and taking BL-11 can significantly increase the level of IGF-1 in serum (P ⁇ 0.01), and the improvement effect is higher than that of Bb-XX.
- This example is used to illustrate the preparation of BL-11 bacterial powder and its use in food production.
- the Bifidobacterium lactis BL-11 provided by the present invention is anaerobic cultured in MRS broth liquid medium.
- the fermentation broth after primary, secondary and expanded culture was cultured at 37°C for 24 hours and then centrifuged at 4°C and 3000 rpm for 10 min to collect the cells, washed with phosphate buffered saline (PBS), and then freeze-dried by adding skim milk. , Store below -20°C.
- PBS phosphate buffered saline
- the BL-11 bacteria powder prepared in this example can be used for food, medicine, health care product or animal feed.
- the food can be common food or health food such as fermented milk, cheese, milk-containing beverage, solid beverage, and milk powder.
- the recommended dose of Bifidobacterium lactis BL-11 for human use may be 1.0 ⁇ 10 3 CFU to 1.0 ⁇ 10 10 CFU/kg body weight/day, more preferably 1.0 ⁇ 10 4 CFU ⁇ 1.0 x 109 CFU/kg body weight/day.
- This example is used to illustrate the functional characterization of growth and development in human clinical studies.
- Subjects and Recruitment 65 patients with Prader-Willi syndrome aged 11 months to 16 years were recruited and randomly assigned to probiotics or placebo for a 12-week randomized, double-blind, placebo-controlled trial.
- Inclusion criteria genetically proven PWS; no probiotics of any kind for four weeks; stable medication for at least four weeks; no planned pharmacological and psychological interventions during the trial; willingness to provide timely stool samples; willingness to participate in the study and interview process, and no other genetic disease, pregnancy or breastfeeding.
- Informed consent was obtained from the subjects' parents or legal guardians as required by the IRB for the research protocol and was conducted in accordance with the Declaration of Helsinki.
- RESULTS Randomized and blinded testing: A randomized double-blind placebo-controlled design was used, with random assignment concealment of subjects by a statistician not part of the team, allowing each unidentified subject to generate a random sample number.
- Beijing Huayuan Institute of Biotechnology provided identical-looking coded probiotics and placebos to ensure allocation concealment and blind spots maintained.
- the patients were randomly assigned to receive daily Bifidobacterium lactis BL- 11 probiotic (6 x 1010 CFU) or placebo bar packs.
- the weight, height, ASQ-3, ABC, SRS-2 and CGI-1 of the two groups were compared at 6 and 12 weeks of treatment.
- CGI consists of two single measures assessing the following: (a) psychopathology severity (CGI-S) from 1 to 7 and (b) change in symptoms before and after treatment on a seven-point scale from start to finish (CGI-S) -I).
- the probiotic group is Bifidobacterium lactis BL-11 in the form of sticks and packs.
- Each bag of Bifidobacterium lactis supplement contains 3 x 10 10 Colony Forming Units (CFU); the placebo is maltodextrin in the same package, similar in color, taste and flavor to Bifidobacterium lactis stick packs.
- Subjects received a sachet of Bifidobacterium lactis or a placebo orally with water twice daily for 12 weeks. Maltodextrin as a supplement had minimal side effects and as a placebo maltodextrin also had minimal adverse effects.
- Weight and height were measured by parents using standard scales and collected by the researchers, using the age-increasing reference provided by WHO as a reference to convert weight, height, and BMI to z-scores.
- ASQ-3 Age and Stage Questionnaire, Third Edition
- the ASQ-3 is one of the most widely used developmental screening tools for children and adolescents and has five dimensions: communication, gross motivation, fine motivation, problem solving, and personal socialization. The subject's total score was calculated according to five dimensions to evaluate the trial effect.
- ABS Abnormal Behavior Inventory
- SRS Social Responsiveness Scale
- Fecal samples were collected in DNA/RNA shielded fecal collection tubes (Zymo, Cat #R1101) containing 1 mL of preservation solution and transported to the laboratory via ice packs and then frozen at -80°C.
- DNA was extracted using the TIANmap Fecal DNA Kit (TIANGEN, cat. no. DP328) according to the manufacturer's instructions, and DNA samples were carefully quantified using a Nanodrop spectrophotometer. The ratio of A260/A280 was measured to confirm the yield of high-purity DNA. DNA samples were frozen at -20°C until use.
- the PCR product was purified with 1xKAPA AMPure (KAPA, cat. no. KK8002) by (95°C for 2 min, then at 95°C for 30s, 55°C for 30s, and 72°C for 30s for 25 cycles) followed by a final extension at 72°C for 5min. , the product was subjected to a second PCR reaction step (95°C for 2 min, followed by eight cycles of 95°C for 30s, 55°C for 30s and 72°C for 30s, and a final extension at 72°C for 5min).
- the PCR product was purified by 1 ⁇ KAPA AMPure , and quantitatively analyzed by real-time PCR using the Bioanalyzer DNA kit.
- CGI Clinical Global Impression
- Gastrointestinal symptoms were assessed based on the total number of gastrointestinal symptoms present at baseline, including constipation, diarrhea, abdominal pain, flatulence, blood in the stool, nausea, dysphagia, loss of appetite, dyspepsia, and acid regurgitation.
- FDRs false discovery rates
- Quality control filtered sequencing reads using QIIME2 (v2019.10).
- the default parameters were denoised using Deblur and the abundance table of the samples was obtained by amplicon sequence variants (ASVs).
- Alpha diversity was calculated using QIIME2.
- Bray-Curtis distance was used to characterize microbiome beta diversity.
- ASVs were assigned using a sklearn based classifier trained on sequences with 99% similarity to Greengenes v13.8. Significant differences in relative abundances of microbial phyla, genera and alpha diversity between the placebo and probiotic groups were confirmed by the Kruskal–Wallis test. False discovery rate (FDR) based on Benjamini-Hochberg (BH) adjustment was used for multiple comparisons.
- FDR False discovery rate
- BH Benjamini-Hochberg
- PICSRUSt2 was used to infer the functional content of microorganisms based on the abundance table of ASVs, and then generated the Kyoto Encyclopedia of Genes and Genomes (KEGG) orthologs (KO), enzyme taxonomy and pathway abundance tables. The ratios between the probiotic and placebo groups were analyzed for differences using permutation-based nonparametric tests, and the most significant differences were plotted with Calour. All raw data from 16s rRNA Illumina amplicon sequencing has been deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA, PRJNA643297).
- NCBI National Center for Biotechnology Information
- Table 4 summarizes the demographic characteristics and comorbid gastrointestinal (GI) symptoms of the 65 participants, and no between-group differences were observed (P>0.05). 47.5% of the subjects showed one or more gastrointestinal symptoms in the study population. Although the proportion of gastrointestinal symptoms in the probiotic group was 37.4% lower than that in the placebo group, the difference did not reach significant (P>0.05). ).
- Bifidobacterium lactis BL-11 subjects experienced a significant increase in height and a slight change in weight.
- the present disclosure provides new evidence for Bifidobacterium lactis BL-11 as an early intervention for PWS patients.
- the present disclosure found that there was a significant difference in gut microbiome beta diversity between the treated probiotic group and the placebo group, with baseline beta diversity directly correlated with long-term weight loss when adhering to a controlled diet. Therefore, supplementation with Bifidobacterium lactis BL-11 may improve gut microbiota composition, prevent obesity or promote diet-induced weight loss. Supplementation with Bifidobacterium lactis BL-11 may also improve the growth and development of children and adolescents.
- This example is used to illustrate the preparation method of BL-11 freeze-dried bacterial powder.
- the BL-11 preserved bacterial solution was recovered in a 37°C water bath until the liquid in the cryopreservation tube was completely thawed; the MRS medium was zoned and streaked, and anaerobic culture at 37°C for 12-24 hours; single colonies were picked and inoculated Put it into an anaerobic culture tube containing a liquid medium, seal it, and cultivate it anaerobically at 37 °C for 6-12 hours. Monitor the OD600 value of the bacterial liquid to stop growing, and stop the fermentation; carry out bacterial fermentation production, and culture at 40 °C with constant temperature stirring for 6 ⁇ 12 hours.
- Add freeze-drying protective agent stir and mix evenly, put it into freeze-drying machine for freeze-drying of bacterial powder; collect freeze-dried powder, pulverize and pack according to quality requirements.
- This example is used to illustrate that BL-11 freeze-dried bacterial powder is used in the production of food.
- the freeze-dried bacteria powder prepared by the Bifidobacterium lactis BL-11 provided by the invention can be used for common food or health food such as yogurt, fermented milk, cheese and the like.
- the dosage of Bifidobacterium lactis BL-11 for making yogurt is 1.0 ⁇ 10 6 CFU ⁇ 1.0 ⁇ 10 8 CFU/kg, more preferably 1.2 ⁇ 10 7 CFU ⁇ 1.5 ⁇ 10 8 CFU/kg.
- the production method is direct investment or post-addition. It is used as a fermentation strain during direct injection. After the raw milk is sterilized, it will be added in proportion when the temperature is reduced to an appropriate temperature, and then fermented at 40-43 °C for 10-48 hours. After mixing and mixing, it is dispensed into cups or bags as finished products.
- adding in the post-adding method after the fermentation of the yogurt is completed, add it according to a certain proportion and stir it evenly.
- This example is used to illustrate that BL-11 freeze-dried bacterial powder is used for the production of dietary nutritional supplements and probiotics.
- the freeze-dried bacteria powder prepared by the Bifidobacterium lactis BL-11 provided by the invention can be used for the production of probiotic bacteria.
- Probiotic lyophilized powder contains 0.5-30 parts of BL-11 lyophilized powder, 5-20 parts of Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus reuteri, Lactobacillus plantarum, Bifidobacterium adolescentis, Bifidobacterium breve Bacillus, Bifidobacterium longum and other strains, 20-70 parts of galacto-oligosaccharides, fructooligosaccharides, inulin and other prebiotics, 5-10 parts of GABA, tryptophan, lycopene, ⁇ -carotene, Nutrients such as vitamin B6, vitamin B12, coenzyme Q10, taurine, pectin, beta-glucan, fucose, carrageenan, guar
- the total dosage of the viable count of probiotics is as follows: the dosage of BL-11 is 2.0 ⁇ 10 6 CFU to 2.0 ⁇ 10 10 CFU/g, more preferably 3 ⁇ 10 7 CFU to 3 ⁇ 10 10 CFU/g.
- the dosage of single bacteria for other strains is 1 ⁇ 10 6 CFU to 3 ⁇ 10 9 CFU/g.
- the preparation process includes: weighing raw materials in proportion, mixing, sub-packaging and quality inspection.
- This example is used to illustrate the effect of BL-11 freeze-dried bacterial powder on improving intestinal permeability and behavior.
- Gut microbes and the gut-brain axis play a two-way communication in the regulation of stress responses.
- Microbes communicate with the gut-brain axis through different mechanisms. Directly interacts with mucosal cells, affects brain development and behavior through immune cells and through contact with nerve endings. Stress in the brain can also have an effect on the gut microbiome through GBA, which is responsible for gastrointestinal dysfunction and dysregulation.
- the stress response also affects the synthesis of microbial by-products and precursors that enter the brain through the blood and hindbrain regions, release cytokines through mucosal immune cells, and release gut hormones such as serotonin through enteroendocrine cells ( 5-HT), or through afferent neural pathways, including the enteric nervous system.
- 5-HT enteroendocrine cells
- probiotic preparations for intervention were freeze-dried powder containing BL-11, ⁇ -carotene, vitamin B6, vitamin B12, coenzyme Q10 and maltodextrin, and the control group was maltodextrin.
- the dose is 10 billion CFU/only/day.
- mice Twenty 6-week-old C57BL/6J mice were housed in groups of 5 mice per cage, with free food and water. Food and water intake were recorded twice a week. The mice were divided into two groups, the control group and the probiotic group, with 10 mice in each group. After one week of acclimatization, the experimental mice were randomly divided into the model group and the probiotic intervention group. The growth environment conditions of the experimental mice were: ambient temperature (23 ⁇ 2)° C., relative humidity (50 ⁇ 10)%, and light mode (12h dark/12h light).
- a chronic stress model was used, and the specific stimulation methods included: (1) fasting for 24 hours; (2) continuous light for 24 hours; (3) iron clips on the tail, 1 cm from the tip of the tail, for 3 min/hour times; (4) restraint stress, circular sleeve restraint action 2h/day. 1-2 different stress stimuli were used every day, and the time of each stimulation was not fixed, and the modeling time lasted for 4 weeks.
- Platform jumping device experimental box (DTT-2 mouse jumping platform, Institute of Materia Medica, Chinese Academy of Medical Sciences).
- the platform box is about 120cm long, 12cm wide and 30cm high, made of plexiglass. It is divided into 6 chambers, each chamber is 12cm long, 12cm wide and 30cm high.
- the experimental box can allow 6 mice to conduct experiments at the same time.
- the bottom of the experimental box is covered with a copper grid, which is connected to the power supply through wires, and the current and voltage are set to 36V.
- An insulating table (a pentagon-shaped wooden block with a long diameter of 5.7 cm, a short diameter of 4.5 cm, and a height of 4.8 cm) was placed on the copper grid in the experimental box near the corner of the box as a safe area for animals to avoid electric shock.
- the test device is connected with a computer automatic recording system.
- the mice were put into the experiment box of the platform jumping apparatus and adapted to the environment for 5 minutes. After that, the mice were gently placed on the platform and the copper grid was energized. When the mice jumped off the platform and touched the copper grid, they would receive an electric shock.
- the normal avoidance response is to jump on the platform to return to the safe area, avoid the electric shock, and study for 5 minutes.
- the memory ability test was carried out, and the mice were placed on the platform, and the time from staying on the platform to the first jump to receive an electric shock, i.e. the latency period and the number of errors within 5 minutes (the mice’s limbs simultaneously contacted the copper grid for electric shock) were recorded. The number of times) was used as an evaluation index of memory function.
- mice in the probiotic group could improve the impairment of one-time avoidance response memory function (see Table 5).
- the opening experiment analysis system is to observe and study the neuropsychiatric changes of experimental animals and various behaviors after entering the open environment. For example, animals are afraid of the new open environment, but they mainly move in the peripheral area, and less in the central area, but the animal's exploratory characteristics In turn, the motivation to act in the central area can also be observed, and the resulting anxiety can also be observed. Used to assess the voluntary active activity and anxiety levels of animals.
- mice 60 minutes before the experiment, the mice were moved to the test room of the opening experiment to adapt to the environment in advance. During the experiment, the mice were taken out of the cage and placed in the behavioral experimental station in the open-field experimental device (box length ⁇ width ⁇ height: 100 cm ⁇ 100 cm ⁇ 40 cm, the inner and bottom surfaces were blue, and a camera was placed just above the central area. After the start of the experiment, put the mouse in a fixed position in the central area, place the head fixed to one side each time, and quickly pull up the hood. After recording the mouse number, date, and status in the operating software, open the recording system, and select Jiugongge Mode, the central area ratio is 0.5, through the camera above the opening equipment and the monitor connected to it.
- Each mouse is measured for 5 minutes, and the activity of the mice is recorded.
- the measurement indicators include exercise time, total distance, and percentage of residence time in the central area (central area).
- Stay time LPMM s), percentage of horizontal movement in central area (horizontal movement distance in central area L horizontal movement distance), percentage of horizontal movement in four-side area (horizontal movement distance in four-side area L horizontal movement distance) and percentage of horizontal movement in four corner areas (horizontal movement in four corner areas) Exercise L horizontal movement distance). Record the number of times of standing and grooming, then clean the environment in the box with 75% alcohol, wait for the alcohol to evaporate and tasteless, and then proceed to the next one. The results are shown in Table 6.
- D-lactic acid is a metabolite of bacterial fermentation, which can be produced by a variety of bacteria in the gut. Even after being ingested from food, it is rarely absorbed into the blood under normal circumstances, and mammals do not have an enzyme system to rapidly degrade it. Therefore, when the permeability of the intestinal mucosa increases, a large amount of D-lactic acid produced by bacteria in the intestinal tract enters the blood through the damaged mucosa, which increases the level of D-lactic acid in the blood.
- D-type and L-type lactic acid There are D-type and L-type lactic acid.
- the normal human body only has L-lactic acid, and microorganisms such as bacteria can produce D-lactic acid.
- Monitoring the level of D-lactic acid in blood can timely reflect the degree of intestinal mucosal damage and changes in permeability. It can be used for the auxiliary evaluation of intestinal infection, endotoxemia, systemic inflammatory response, repeated fever, vomiting, etc.
- LPS Lipopolysaccharide
- lipid A lipid A
- core oligosaccharide lipid A
- hypervariable polysaccharide domain O antigen.
- the structure of LPS determines its agonist/antagonist action on TLR4.
- LPS binds to the TLR4/MD-2 receptor complex and activates different signaling pathways through Myd88-dependent or TRIF-dependent pathways; the expression of TLR in different parts of intestinal epithelial cells is different, which can prevent the inflammatory response caused by LPS , and against pathogenic bacteria.
- Bacterial translocation is the movement of live intestinal bacteria from the gut across the epithelial mucosa into the body. Bacteria can enter the lymphatic system via the mesenteric lymph nodes and circulate throughout the body. Bacteria can also enter the blood circulation, causing bacteremia, and can also localize in tissues. Bacterial displacement can lead to bacterial overgrowth in the small intestine, intestinal damage and shock. Any stress response, both psychological and physiological, that leads to gut permeability could potentially lead to bacterial displacement.
- LPS is associated with the pathogenesis of various diseases, such as intestinal diseases such as IBD and enterocolitis, and even Parkinson's and Alzheimer's diseases. LPS can not only enter the blood, but also enter and remain in the brain for a lifetime, possibly causing Alzheimer's disease.
- the level of LPS in the blood can reflect the permeability of the intestinal tract.
- the normal intestinal barrier does not allow the entry of LPS.
- a higher level of LPS in the blood indicates that the intestinal bacteria or LPS has migrated to the blood, indicating that the intestinal tract is permeable.
- the amount of LPS in the blood can also indicate the inflammatory response and stress state. Too much LPS can cause abnormality of the human immune system, chronic or acute inflammatory response, and acute inflammation such as fever and pain. It can be used for the auxiliary evaluation of intestinal infection, endotoxemia, systemic inflammatory response, repeated fever, vomiting, mental illness, stress response, etc.
- the intestinal barrier function analysis system JY-DLT, Beijing Zhongsheng Jinyu Diagnostic Technology Co., Ltd. was used to detect the content of D-lactic acid and LPS in serum according to the operating instructions.
- This example is used to illustrate the effect of BL-11 freeze-dried bacterial powder on intestinal microbial composition.
- Bacterial 16S rRNA gene amplification using the diluted genomic DNA as the template, according to the selection of the sequencing region, using specific primers with Barcode, using bacterial universal primers 341F (CCTAYGGGRBGCASCAG SEQ ID NO.3) and 806R (GGACTACNNGGGTATCTAAT SEQ ID NO. 4) Amplify the V3-V4 region of the bacterial 16S rRNA gene. 100 ng of extracted DNA was subjected to PCR for strand renaturation at 56°C, starting with 4 minutes of denaturation at 94°C, followed by 30 cycles of 94°C for 30 seconds, 56°C for 30 seconds, and 72°C for 1 minute.
- Amplicon gene sequencing The library construction kit of Illumina's TruSeq DNA PCR-Free Library Preparation Kit was used to construct the library. The constructed library was quantified and tested by Qubit. After passing the test, the Illumina HiSeq2500PE250 sequencing platform was used for bacterial population sequencing. .
- the raw data of bacterial population sequencing was imported into QIIME (2019.4), denoised with DADA2 to obtain representative amplicon variants (ASVs) and constructed a phylogenetic tree. After quality control, the filtered ASVs were The bayes classifier (NBC) method was used for alignment and species annotation with gene sequences in the Greengenes (V_13.5) database. In performing Alpha and Beta diversity analyses, the resampling depth was 10,000 sequences per sample to ensure sufficient sequences. In order to reduce the influence of too many species on the results, the statistical results were corrected by calculating the false discovery rate (FDR).
- FDR false discovery rate
- This example is used to illustrate the results of the intervention of probiotics consisting of BL-11 bacteria on children diagnosed with autism spectrum disorder (ASD) at the age of 3 years and 6 months.
- ASD autism spectrum disorder
- the taking cycle is 90 days.
- the child's defecation habits have changed.
- the frequency of defecation has been changed from once every 3-5 days to once every 1-2 days.
- Parents reported that the child's vocabulary expression ability, socialization and eye contact frequency increased, and the words spoken Increase the volume by 3-5 words.
- the frequency of active feedback on their own feelings has increased, and the number of active requests has increased. There were fewer repetitive movements than before the intervention. The parents chose to continue taking it, and the continuous improvement is still being observed and recorded.
- This example is used to illustrate the improvement of attention hyperactivity deficit disorder (ADHD) by probiotics composed of BL-11 bacteria.
- ADHD attention hyperactivity deficit disorder
- the treatment method is oral probiotic freeze-dried powder treatment, dosage: 2 times a day, 60 billion CFU each time. Take it with warm water in the morning and after dinner, respectively. Continuous treatment for 12 weeks. Conners parent questionnaire was used for assessment, including behavior, somatic, anxiety, learning, hyperactivity, and other indicators. The results showed that the children had lower scores on impulsivity, anxiety, and hyperactivity, improved bowel function, from once every 3-4 days to 1-2 times a day, sometimes once every 2-3 days, increased stool volume, and The bloating and pain gradually disappeared. The overall mental health improved markedly. Parents are satisfied with the results.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
错误次数(次) | 潜伏期(S) | |
对照组 | 1.45±0.82 | 268.32±50.63 |
益生菌组 | 1.07±0.87 | 248.05±82.33 |
P value | 0.0348 | 0.0782 |
行为 | 学习 | 心身 | 冲动 | 焦虑 | 多动 | |
治疗前 | 1.6 | 2.1 | 0.35 | 1.34 | 0.52 | 1.38 |
治疗后 | 1.2 | 1.8 | 0.29 | 1.32 | 0.35 | 1.23 |
Claims (20)
- 一种乳双歧杆菌,该乳双歧杆菌为乳双歧杆菌BL-11,其特征在于,所述乳双歧杆菌BL-11的保藏编号为CGMCC No.20847。
- 一种乳双歧杆菌制剂,其中,所述制剂为固态菌粉或者液态饮液;所述乳双歧杆菌为权利要求1所述的乳双歧杆菌。
- 权利要求1所述的乳双歧杆菌在制备改善肠道代谢紊乱促进肠道微生物组组成正常化的食品组合物或药物组合物中的应用。
- 权利要求1所述的乳双歧杆菌在制备儿童青少年抗肥胖的食品组合物或药物组合物中的应用。
- 权利要求1所述的乳双歧杆菌在制备促进儿童青少年生长发育的食品组合物或药物组合物中的应用。
- 权利要求1所述的乳双歧杆菌在制备促进儿童青少年身高增加的食品组合物或药物组合物中的应用。
- 权利要求1所述的乳双歧杆菌在制备促进儿童青少年智力发展的食品组合物或药物组合物中的应用。
- 根据权利要求3-7中任意一项所述的应用,其中,相对于100重量份的食品组合物或药物组合物,所述乳双歧杆菌BL-11的含量为1-25重量份,优选为1-15重量份;所述乳双歧杆菌BL-11以所述乳双歧杆菌BL-11的活菌体、所述乳双歧杆菌BL-11的灭活菌体或所述乳双歧杆菌BL-11的提取物的形式使用;所述乳双歧杆菌BL-11的活菌数为1.0×10 6~1.5×10 12CFU/g,优选为3.0×10 10~5.0×10 11CFU/g。
- 根据权利要求3-7中任意一项所述的应用,其中,所述食品组合物是发酵乳、乳酪、含乳饮料、固体饮料、乳粉中的一种或多种。
- 根据权利要求3-7中任意一项所述的应用,其中,以人体体重为基准,所述乳双歧杆菌BL-11的服用剂量为2.0×10 9CFU~1.5×10 11CFU/kg/天,优选为3.0×10 4CFU~8.0×10 10CFU/kg/天。
- 权利要求1所述的乳双歧杆菌在制备防治精神障碍的食品组合物或药物组合物中的应用。
- 根据权利要求11所述的应用,其中,所述精神障碍包括焦虑、抑郁、注意缺陷多动障碍、自闭症、孤独症、精神分裂症、肝性脑病、神经性厌食症、妥瑞症、艾斯伯格症候群。
- 根据权利要求11所述的应用,其中,所述食品组合物或药物组合物还含有脱脂奶粉、海藻糖、低聚果糖、乳糖、葡萄糖、蔗糖、L-抗坏血酸钠、L-苹果酸、L-乳酸等的一种或几种组合。
- 根据权利要求11所述的应用,其中,所述食品组合物或药物组合物还含有 调味剂、甜味剂、增稠剂、稳定剂、表面活性剂、润滑剂、酸性中和剂、分散剂、缓冲液或缓冲剂、脱苦剂、pH稳定剂、防腐剂、脱糖剂和/或着色剂,如乳糖醇、山梨糖醇、麦芽糖醇、阿斯巴甜、甜叶菊、罗汉果、三氯蔗糖、木糖醇、香草、巧克力、水果香料、人造香精、或者它们的混合物或组合。
- 根据权利要求11所述的应用,其中,所述食品组合物或药物组合物还含有维生素、矿物质和/或膳食补充剂或益生元营养物质、至少一种益生元,其中任选地,所述益生元包括菊粉、洋蓟提取物、菊苣根提取物、菊芋根提取物、低聚果糖、低聚半乳糖、低聚异麦芽、低聚木糖、水苏糖、低聚甘露糖、低聚阿拉伯糖、抗性糊精、抗性淀粉或者它们的混合物或组合。
- 根据权利要求11所述的应用,其中,所述食品组合物或药物组合物还含有泛醌(CoQ10)、番茄红素、β-胡萝卜素、色氨酸、维生素B6、维生素B12或者它们的混合物或组合。
- 根据权利要求11所述的应用,其中,所述食品组合物或药物组合物还含有益生菌,其中任选地,所述益生菌包括培养的或粪便中提取的微生物或细菌或细菌组分,并且任选地,所述细菌或细菌组分包括或者来源于乳酸杆菌(Lactobacillus)、双歧杆菌(Bifidobacterium)、大肠杆菌(E coli)、普雷沃氏杆菌(Prevotella)、粪栖杆菌(Faecalibacterium)、布劳特氏菌(Blautia)、拟杆菌(Bacteroidetes)、厚壁菌(Firmicutes)以及等同物,或者它们的混合物或组合。
- 根据权利要求11-17中任意一项所述的应用,其中,相对于100重量份的食品组合物或药物组合物,所述乳双歧杆菌BL-11的含量为0.5-20重量份,优选为1-15重量份;所述乳双歧杆菌BL-11以所述乳双歧杆菌BL-11的活菌体、所述乳双歧杆菌BL-11的灭活菌体或所述乳双歧杆菌BL-11的提取物的形式使用;所述乳双歧杆菌BL-11的活菌数为1.0×10 6~1.5×10 12CFU/g,优选为3.0×10 10~5.0×10 11CFU/g。
- 根据权利要求11-17中任意一项所述的应用,其中,所述食品组合物是发酵乳、乳酪、含乳饮料、固体饮料、乳粉中的一种或多种。
- 根据权利要求11-17中任意一项所述的应用,其中,以人体体重为基准,所述乳双歧杆菌BL-11的服用剂量为2.0×10 9CFU~1.5×10 11CFU/kg/天,优选为3.0×10 4CFU~8.0×10 10CFU/kg/天。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22752363.6A EP4293103A1 (en) | 2021-02-10 | 2022-04-08 | Bifidobacterium lactis and application thereof |
CA3208064A CA3208064A1 (en) | 2021-02-10 | 2022-04-08 | Bifidobacterium animalis subsp. lactis and use thereof |
KR1020237030867A KR20230170647A (ko) | 2021-02-10 | 2022-04-08 | 비피도박테리움 락티스 및 그 사용 |
JP2023549064A JP2024507187A (ja) | 2021-02-10 | 2022-04-08 | ビフィドバクテリウム・ラクティス及びその使用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110185144 | 2021-02-10 | ||
CN202110185142.X | 2021-02-10 | ||
CN202110185142 | 2021-02-10 | ||
CN202110185144.9 | 2021-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022171203A1 true WO2022171203A1 (zh) | 2022-08-18 |
Family
ID=82838175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/085752 WO2022171203A1 (zh) | 2021-02-10 | 2022-04-08 | 一种乳双歧杆菌及其应用 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4293103A1 (zh) |
JP (1) | JP2024507187A (zh) |
CA (1) | CA3208064A1 (zh) |
WO (1) | WO2022171203A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115505543A (zh) * | 2022-09-28 | 2022-12-23 | 天津小薇生物科技有限公司 | 一株乳双歧杆菌br001及其发酵方法与改善过敏的应用 |
CN116369527A (zh) * | 2023-03-09 | 2023-07-04 | 江南大学 | 一株可调节骨骼发育的短双歧杆菌及其应用 |
CN116746683A (zh) * | 2023-08-01 | 2023-09-15 | 河北源民生物科技有限公司 | 防消化不良胀气、促吸收的动物双歧杆菌乳亚种bal-28及发酵产物、菌群cw和应用 |
CN116769654A (zh) * | 2023-06-14 | 2023-09-19 | 内蒙古农业大学 | 一株动物双歧杆菌乳亚种及其应用 |
CN117025489A (zh) * | 2023-10-09 | 2023-11-10 | 杭州微致生物科技有限公司 | 一种动物双歧杆菌乳亚种vb315及其应用 |
CN117431190A (zh) * | 2023-12-14 | 2024-01-23 | 深圳未知君生物科技有限公司 | 一株能够缓解自闭症谱系障碍的短双歧杆菌及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105603066A (zh) * | 2016-01-13 | 2016-05-25 | 金锋 | 精神障碍的肠道微生物标志物及其应用 |
US20170252382A1 (en) * | 2014-08-29 | 2017-09-07 | Chr. Hansen A/S | Probiotic bifidobacterium adolescentis strains |
CN109069554A (zh) * | 2016-04-14 | 2018-12-21 | 杜邦营养生物科学有限公司 | 用于降低食物、能量和/或脂肪摄入的双歧杆菌 |
CN112956696A (zh) * | 2021-02-10 | 2021-06-15 | 北京华元生物技术研究院 | 乳双歧杆菌在防治精神障碍中的用途 |
CN112980725A (zh) * | 2021-02-10 | 2021-06-18 | 北京华元生物技术研究院 | 一种乳双歧杆菌及其在促进儿童青少年生长发育中的用途 |
-
2022
- 2022-04-08 JP JP2023549064A patent/JP2024507187A/ja active Pending
- 2022-04-08 EP EP22752363.6A patent/EP4293103A1/en active Pending
- 2022-04-08 CA CA3208064A patent/CA3208064A1/en active Pending
- 2022-04-08 WO PCT/CN2022/085752 patent/WO2022171203A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170252382A1 (en) * | 2014-08-29 | 2017-09-07 | Chr. Hansen A/S | Probiotic bifidobacterium adolescentis strains |
CN105603066A (zh) * | 2016-01-13 | 2016-05-25 | 金锋 | 精神障碍的肠道微生物标志物及其应用 |
CN109069554A (zh) * | 2016-04-14 | 2018-12-21 | 杜邦营养生物科学有限公司 | 用于降低食物、能量和/或脂肪摄入的双歧杆菌 |
CN112956696A (zh) * | 2021-02-10 | 2021-06-15 | 北京华元生物技术研究院 | 乳双歧杆菌在防治精神障碍中的用途 |
CN112980725A (zh) * | 2021-02-10 | 2021-06-18 | 北京华元生物技术研究院 | 一种乳双歧杆菌及其在促进儿童青少年生长发育中的用途 |
Non-Patent Citations (3)
Title |
---|
"Digestive Diseases and Microecology", 31 March 2001, SHANGHAI SCIENCE AND TECHNOLOGY PRESS, CN, ISBN: 978-7-5323-5829-8, article ZHANG, RONGDA: "Brief Clinical Description of Bifidobacterium", pages: 228 - 229, XP009539016 * |
KONG XUE-JUN, ET AL: "The Effects of Probiotic Supplementation on Anthropometric Growth and Gut Microbiota Composition in Patients With Prader-Willi Syndrome: A Randomized Double-Blinded Placebo-Controlled Trial", FRONTIERS IN NUTRITION, vol. 8, XP055950467, DOI: 10.3389/fnut.2021.587974 * |
QU WAN, LIU SHUO; MA CHEN;YAN HE: "Effects of Two Probiotics on the Characteristics of Behavior and Intestinal Microbiota of the Depressed Model Rat", JOURNAL OF CHINESE INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, CHINESE INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, CN, vol. 20, no. 12, 31 December 2020 (2020-12-31), CN , pages 114 - 121, XP055959453, ISSN: 1009-7848 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115505543A (zh) * | 2022-09-28 | 2022-12-23 | 天津小薇生物科技有限公司 | 一株乳双歧杆菌br001及其发酵方法与改善过敏的应用 |
CN115505543B (zh) * | 2022-09-28 | 2024-01-26 | 天津小薇生物科技有限公司 | 一株乳双歧杆菌br001及其发酵方法与改善过敏的应用 |
CN116369527A (zh) * | 2023-03-09 | 2023-07-04 | 江南大学 | 一株可调节骨骼发育的短双歧杆菌及其应用 |
CN116769654A (zh) * | 2023-06-14 | 2023-09-19 | 内蒙古农业大学 | 一株动物双歧杆菌乳亚种及其应用 |
CN116746683A (zh) * | 2023-08-01 | 2023-09-15 | 河北源民生物科技有限公司 | 防消化不良胀气、促吸收的动物双歧杆菌乳亚种bal-28及发酵产物、菌群cw和应用 |
CN117025489A (zh) * | 2023-10-09 | 2023-11-10 | 杭州微致生物科技有限公司 | 一种动物双歧杆菌乳亚种vb315及其应用 |
CN117025489B (zh) * | 2023-10-09 | 2024-03-19 | 杭州微致生物科技有限公司 | 一种动物双歧杆菌乳亚种vb315及其应用 |
CN117431190A (zh) * | 2023-12-14 | 2024-01-23 | 深圳未知君生物科技有限公司 | 一株能够缓解自闭症谱系障碍的短双歧杆菌及其应用 |
CN117431190B (zh) * | 2023-12-14 | 2024-03-12 | 深圳未知君生物科技有限公司 | 一株能够缓解自闭症谱系障碍的短双歧杆菌及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CA3208064A1 (en) | 2022-08-18 |
EP4293103A1 (en) | 2023-12-20 |
JP2024507187A (ja) | 2024-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022171203A1 (zh) | 一种乳双歧杆菌及其应用 | |
WO2022218336A1 (zh) | 罗伊氏乳杆菌在制备预防或治疗发育障碍类疾病产品中的应用 | |
KR20230170647A (ko) | 비피도박테리움 락티스 및 그 사용 | |
JP2019031516A (ja) | プレバイオティクスとしての、精製された2’−フコシルラクトース、3−フコシルラクトース、およびラクトジフコテトラオースの使用 | |
KR20190011806A (ko) | 박테리아 균주를 포함하는 조성물 | |
JP2024516950A (ja) | ラクトバチルス・ロイテリ及びその使用、組成物、医薬品及び食品 | |
EP3398446A1 (en) | Bifidobacterium longum and hippocampal bdnf expression | |
JP2017533915A (ja) | 過敏性腸症候群の治療のための合成組成物および方法 | |
KR20200091438A (ko) | 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물 | |
CN108348535A (zh) | 用于调节脑功能和行为的合成组合物和方法 | |
Hickey et al. | Probiotics in neonatology | |
EP3484585B1 (en) | Use of probiotics in the treatment and/or prevention of atopic dermatitis | |
CA3138520C (en) | Probiotic bacterial strains that produce short chain fatty acids and compositions comprising same | |
CN112980725B (zh) | 一种乳双歧杆菌及其在促进儿童青少年生长发育中的用途 | |
AU2008310961B2 (en) | Probiotics for use in relieving symptoms associated with gastrointestinal disorders | |
JP2022517754A (ja) | 菌株、組成物および使用方法 | |
JP2022504185A (ja) | 細菌株を含む組成物 | |
EP3965820A1 (en) | Compositions and methods for promoting healthy neural development in an unborn baby | |
KR20230131850A (ko) | 아동의 성장 및 사회 기능을 향상시키기 위한 프로바이오틱스조성물 및 이의 사용 방법 | |
WO2020247536A1 (en) | Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies | |
US20190091270A1 (en) | Probiotics for use in relieving symptoms associated with gastrointestinal disorders | |
JP7523493B2 (ja) | 情動的反応を制御するため、並びに潜在的な気分変調の治療及び予防のための、ビフィドバクテリウム・ロンガムを用いる、方法及び組成物 | |
Gayathri et al. | Gut-Brain Axis: Probiotic Interactions and Implications for Human Mental Health | |
TW202135842A (zh) | 包含細菌品系之組合物 | |
TW202128199A (zh) | 包含細菌品系之組合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22752363 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023549064 Country of ref document: JP Ref document number: 3208064 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237030867 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022752363 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022752363 Country of ref document: EP Effective date: 20230911 |